Luxturna Kit
NDC 71394-415
Product Information
Luxturna (voretigene neparvovec-rzyl) is a BLA-approved product labeled by Spark Therapeutics, Inc.. This medication is used to treat a certain inherited eye condition (retinal dystrophy). It is supplied as a kit. This product entry covers the primary NDC 71394-415 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 71394-415?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- VORETIGENE NEPARVOVEC (UNII: 2SPI046IKD)
- VORETIGENE NEPARVOVEC (UNII: 2SPI046IKD) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)
- SODIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: 94255I6E2T)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- POLOXAMER 188 (UNII: LQA7B6G8JG)
- WATER (UNII: 059QF0KO0R)
- SODIUM PHOSPHATE, MONOBASIC (UNII: 3980JIH2SW)
- SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1995884 - voretigene neparvovec-rzyl 5,000,000,000,000 VECTOR-GENOMES/ML in 0.5 ML Injection
- RxCUI: 1995884 - 0.5 ML voretigene neparvovec-rzyl 5000000000000 VECTOR-GENOMES/ML Injection
- RxCUI: 1995884 - voretigene neparvovec-rzyl 5,000,000,000,000 VECTOR-GENOMES/ML per 0.5 ML Injection
- RxCUI: 1995886 - Luxturna 5,000,000,000,000 VECTOR-GENOMES/ML in 0.5 ML Injection
- RxCUI: 1995886 - 0.5 ML voretigene neparvovec-rzyl 5000000000000 VECTOR-GENOMES/ML Injection [Luxturna]
* Please review the full disclaimer at the bottom of this page.